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Abstract 
The phase III BSBMT/UKMF Myeloma X trial (MMX) demonstrated prospectively, for the 
first time, superiority of salvage autologous stem cell transplantation (ASCT2) over 
chemotherapy maintenance for multiple myeloma (MM) in first relapse after prior ASCT 
(ASCT1).  However, many patients have insufficient stored stem cells (PBSC) for ASCT2 
and robust evidence for remobilisation after ASCT1 is lacking.  We therefore report on 
the feasibility, safety and efficacy of remobilisation after bortezomib-doxorubicin-
dexamethasone reinduction in MMX, and outcomes of ASCT2 with these cells.  110 
patients underwent A? ? remobilisation with 32 and 4 respectively undergoing second and 
third attempts.  Toxicities of remobilisation were similar to those seen in first line 
mobilisation.  After all attempts, 52% of those with insufficient previously stored PBSC 
had harvested sufficient to proceed to ASCT2.  Median PBSC doses infused, neutrophil 
engraftment and time to discharge after ASCT2 were similar irrespective of stem cell 
source, as were the toxicities of ASCT2.  No significant differences between PBSC 
sources were noted in depth of response to ASCT or time to progression.  Harvesting 
after bortezomib-doxorubicin-dexamethasone re-induction for MM at first relapse is 
safe and feasible, and yields a reliable cell product for second ASCT.  The study is 
registered with ClinicalTrials.gov (NCT00747877) and EudraCT (2006-005890-24). 
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Introduction 
The demonstration of the efficacy of high dose melphalan in 1983
1
, and later autologous 
stem cell transplant (ASCT), for multiple myeloma (MM), ushered in a new era of MM 
therapy.  Subsequent randomised controlled trials demonstrated improved response 
rates and in some studies improved progression-free (PFS) and overall survival (OS) 
compared to conventional chemotherapy
2-7
; as a result ASCT quickly became 
established front line therapy for patients deemed sufficiently fit.  The incorporation of 
newer biological  ‘ŶŽǀĞůĂŐĞŶƚƐ ? (thalidomide, lenalidomide and bortezomib) into 
induction, consolidation and maintenance regimens has since allowed further 
improvements in the outcomes of ASCT for myeloma in first line therapy
8-15
 (reviewed 
in
16
). 
 
Unfortunately, despite advances in therapy, the vast majority of patients with MM 
relapse, and although widely adopted for front line treatment and often used in relapse, 
the role of ASCT in the management of relapsed disease (salvage ASCT) had until 
recently not been rigorously assessed.  The randomised, open-label, phase III 
BSBMT/UKMF Myeloma X trial (MM X) compares high-dose melphalan plus salvage 
ASCT (HDT-ASCT) against weekly cyclophosphamide (C-weekly) after re-induction with 
PAD (bortezomib, doxorubicin and dexamethasone) for relapsed MM, and has shown a 
clear benefit in time to progression (TTP) for those patients receiving ASCT
17
.  In light of 
this strong evidence, a salvage ASCT should be considered at first relapse for all 
transplant-eligible patients having an initial response to ASCT of >18 months.  Crucially, 
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however, the modality is often considered only for those with sufficient stored stem 
cells from their initial harvest. 
 
Peripheral blood stem cell (PBSC) collection after first induction therapy is a well-
validated and widely employed practice in myeloma therapy worldwide
18
; it is 
convenient and safe and results in enhanced granulocyte and platelet engraftment 
compared to bone marrow-derived stem cells
19-21
.  What is less clear, is whether stem 
cells can be successfully mobilised and harvested after re-induction therapy for patients 
relapsing after first line ASCT.  The impact of previous treatment on the stem cells and 
their niche, and whether such cells constitute a safe, reliable and equivalent product for 
subsequent ASCT require clarification.  As a secondary endpoint of the MM X trial we 
therefore evaluated the feasibility of PBSC mobilisation after re-induction therapy for 
first relapse after prior ASCT. 
Methods 
Study design and patients 
The NCRI Myeloma X Relapse (Intensive) phase 3 trial is a randomised, multi-centre, 
open-label, parallel-group comparison between salvage ASCT and C-weekly as 
consolidation after PAD reinduction for multiple myeloma at first relapse or progressive 
disease (Figure 1).  Patients were recruited from 51 NHS hospitals and were eligible if 
they were over 18 years of age, required treatment for first relapse or progressive 
disease at least 18 months after a previous ASCT (reduced to 12 months in 2011
22
) and 
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were deemed fit enough to undergo intensive treatment.  Patients were excluded if they 
had received therapy for their relapsed disease, had an ECOG performance status of 3-4, 
grade 2 peripheral neuropathy, known resistance to PAD, or comorbidity that would 
preclude high-dose chemotherapy.  Full details of inclusion and exclusion criteria for the 
trial, sample size, laboratory testing at trial entry, ethical review and composition of the 
trial management group are published elsewhere
17
.  The study is registered with 
ClinicalTrials.gov (NCT00747877) and EudraCT (2006-005890-24). 
 
Disease and response assessments 
Response and disease progression were assessed according to the IMWG uniform 
response criteria
23
 and were confirmed by a central laboratory and by an independent 
myeloma physician masked to treatment allocation at baseline, after re-induction, 100 
days after ASCT (or 30 days after C-weekly), every year after randomisation and at 
disease progression.  Full details of cytogenetic analysis are available in Cook et al.
17
. 
 
Trial procedures, randomisation and masking 
All patients received re-induction chemotherapy with 2-4 cycles of PAD (intravenous (IV) 
twice weekly bortezomib and IV doxorubicin with oral dexamethasone; those achieving 
A?s'WZĂĨƚĞƌƚǁŽĐǇĐůĞƐĚŝƐĐŽŶƚŝŶƵĞĚW ?ƚŚĞƌĞŵĂŝŶĚĞƌĐŽntinued to four cycles unless 
precluded by toxicity); those with complete response (CR), partial response (PR) or 
stable disease (SD) were eligible to proceed to the randomisation if they had an 
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ĂĚĞƋƵĂƚĞƐƚĞŵĐĞůůĚŽƐĞƐƚŽƌĞĚ ?ĚĞĨŝŶĞĚĂƐA? ?ǆ ? ?6 CD34+ cells ƉĞƌŬŐ ?ŽƌA? ?ǆ ? ?8
peripheral blood mononuclear cells per kg) and no clinical evidence of deterioration in 
cardiac function since registration.  Patients without an adequate stem cell dose 
underwent PBSC mobilisation and harvesting, and could then proceed if an adequate 
dose was available (combining previously stored and re-harvested cells).  Those with an 
adequate dose already stored prior to trial entry could also undergo mobilisation and 
harvesting at clinician and patient discretion.  Mobilisation regimens were at the 
discretion of treating physicians (see results section and Figure 2).  Patients eligible to 
proceed were then randomly assigned on a 1:1 basis to receive either high dose 
melphalan and ASCT or weekly cyclophosphamide; those receiving C-weekly will not be 
considered further in this report.  Patients randomised to the HDT-ASCT arm received a 
single infusion of intravenous melphalan (200mg/m
2
) followed by PBSC infusion after 24 
to 48 hours.   
 
Outcomes 
The primary endpoint was TTP (published elsewhere
17
); secondary endpoints were 
objective response, progression-free survival, overall survival, pain and quality of life, 
and assessment of the feasibility, safety and efficacy of stem cell remobilisation and the 
outcomes when these PBSC are used for subsequent ASCT.  Toxicity and safety were 
assessed using NCI CTCAE criteria (version 3.0). 
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Statistical methods 
Full details of statistical methods are given in the supplementary material. 
Results 
Enrolment 
Between April 2008 and November 2012, 297 patients were registered (Figure 1), 293 of 
whom went on to receive treatment with PAD induction
17
.  276 patients (92.9%) had at 
least stable disease and remained in the trial after re-induction therapy  ? these patients 
were eligible for randomisation to either high-dose melphalan and ASCT rescue or oral 
cyclophosphamide only if they had adequate stem cells available to allow ASCT (>2x10
6
 
CD34
+
 /kg).  170 patients (57.2%) already had some stem cells stored at trial entry 
(median dose 3.3x10
6
 CD34
+
 /kg, range 0.6-13) of whom 149 (50.2%) had a sufficient 
dose to proceed to ASCT (>2x10
6
 CD34
+
/kg): Figure 1.  26 patients with an adequate 
stored dose elected to undergo re-harvesting anyway, along with 84 of the 127 patients 
without sufficient stored cells.  Mobilisation and peripheral blood stem cell (PBSC) 
collection was therefore undertaken within the trial for 110 patients, of whom 26 
(23.6%) already had an adequate dose stored.  Patient characteristics are illustrated in 
Table 1.  Of patients with at least stable disease and without adequate stored cells, 
harvesting was not undertaken in 43 (33.9%), due to clinician decision (n=22), death 
(n=17; due to progressive disease in n=13), withdrawal from the trial (n=3), or 
progressive disease (n=1).  After all harvesting attempts, 193 patients (65.0%) remained 
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in remission and had adequate stored cells to proceed; 174 were then randomised to 
either high-dose melphalan with ASCT rescue (n=89) or oral cyclophosphamide (n=85).   
 
Harvesting procedures 
Of the 110 patients who underwent PBSC harvesting, 78 (70.9%) underwent only one 
attempt at mobilisation, 28 (25.5%) tried twice, and 4 (3.6%) patients made three 
attempts.  The first mobilisation was a median of 21 days after the last cycle of PAD 
(range 1-126).  Mobilisation regimens were at the discretion of treating physicians, and 
are illustrated in Figure 2 (see also Supplementary Table 1).  Of the 110 remobilised 
patients, 54 (49.1%) achieved a satisfactory cell dose after all attempts: 41 (37.3%) at 
the first mobilisation attempt (yield unknown, n=23), 10 (31.3%) at the second attempt 
(yield unknown, n=6) and 3 (75%) at the third attempt.  There was no difference in 
yields between first, second and third attempts (p=0.9699, Kruskal-Wallis test).  Two 
patients (1.8%) withdrew during PBSC mobilisation, 7 (6.4%) died during mobilisation (6 
with progressive disease: 5.5%, 1 (0.9%) with infection), 1 (0.9%) patient had progressive 
disease and was ineligible to continue and 30 patients (27.3%) did not mobilise sufficient 
stem cells after all attempts.  Taking into account previously stored as well as re-
harvested cells, 70 patients (63.6%) of the 110 who underwent re-harvesting were 
therefore able to proceed to randomisation.  Since 26 of these patients already had an 
adequate stored PBSC dose, 44 (52%) of the 84 patients without an adequate stored 
dose had achieved an adequate PBSC collection and were able to proceed.  Adverse 
events occurring between completion of induction therapy and randomisation to 
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consolidation therapy are shown in Table 2.  Although sensory neuropathy was reported 
during stem cell harvesting, when this was compared to adverse events reported during 
PAD treatment the prevalence and severity of sensory neuropathy was in general lower 
during PBSC harvesting (80% of patients experienced a lower grade of sensory 
neuropathy during stem cell harvesting than at the end of PAD, Supplementary Table 2), 
implying that as might be anticipated this toxicity is secondary to PAD therapy rather 
than PBSC mobilisation and harvesting. 
 
ASCT procedures 
89 patients were randomised to receive HDT and ASCT rescue, of whom 83 (93.3%) 
completed the procedure.  Of these, 42 (50.6%) received stem cells stored prior to trial 
entry (PBSC1), 29 (34.9%) received cells harvested after PAD (PBSC2) and 11 (13.3%) 
received a combination of cells from the two sources (PBSCMix); the stem cell source is 
unknown for one patient.  These groups were not matched within the trial protocol, but 
had broadly similar pre-ASCT characteristics (Table 1).  Gender, age, paraprotein heavy 
and light chain isotypes, previous therapies, response to prior ASCT, and blood results 
(e.g. haemoglobin, platelet count, creatinine clearance, bilirubin, alanine 
aminotransferase) at randomisation were not significantly different between groups.  
Time from registration to randomisation was longer in PBSC2 and PBSCMix than PBSC1, 
reflecting the additional time taken for stem cell mobilisation and harvesting.  Some 
differences between groups were noted in ISS stage at diagnosis, PFS after 1
st
 ASCT, 
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time from diagnosis to randomisation and 13q deletion (Table 3); these are discussed 
further below. 
 
Median stem cell doses infused, neutrophil engraftment and time to discharge were 
similar across groups (p>0.05 in each case; Table 3).  Although the stem cell dose infused 
was not significantly different between groups, the slightly lower dose in the PBSCMix 
group may account for the non-significantly prolonged time to discharge in that group: 
PBSCMix: 18 days, PBSC2: 16 days, PBSC1: 16 days (p=0.4980).  Platelet engraftment was 
also slightly slower in PBSC2 and PBSCMix than PBSC1, again possibly reflecting the 
slightly lower median stem cell dose.  Adverse events reported during high dose 
melphalan and ASCT consolidation were in line with published reports and are shown in 
Supplementary Table 3.  No significant differences were seen in toxicities according to 
stem cell source.  Only 9 serious adverse events (SAEs) were reported in relation to ASCT 
(infection n=6, 7.3%; GI disturbance n=1, 1.2%; neoplasia n=2, 2.4%) thus no inferences 
are made about the frequency of SAEs or readmission in relation to PBSC source. 
 
Outcomes 
Maximal responses to ASCT are shown in Supplementary Table 4.  An ordinal logistic 
regression showed no differences between stem cell sources in terms of response to 
ASCT (X
2
 = 1.53 with 2 degrees of freedom, p=0.4647, adjusting for the trial stratification 
factors).  Median TTP was as follows: PBSC1: 18 months (95% CI: 13-27), PBSC2: 24 
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months (19-28), PBSCMix: 33 months (11-A? ? ?ƉA?0.3553 (Figure 3).  Hazard ratios for TTP 
as compared with PBSC1: PBSC2 0.85 (95% CI: 0.45-1.63), PBSCMix: 0.49 (0.19-1.3).   
Discussion 
The MM X trial has demonstrated for the first time in a prospective multi-centre 
randomised phase III study that following bortezomib-doxorubicin-dexamethasone re-
induction for MM at first relapse, salvage ASCT results in significantly longer TTP than 
chemotherapy consolidation therapy.  Clearly, this finding will be of crucial importance 
for patients and myeloma physicians when choosing therapy for transplant-eligible 
patients relapsing after a prior ASCT.  However, this therapeutic option naturally 
depends on the availability of stored stem cells for ASCT  ? a resource no longer 
remaining for many patients after their first ASCT.  Key questions, therefore, are 
whether it is feasible and safe to mobilise and harvest stem cells from such patients 
after re-induction therapy, and whether those stem cells are suitable for subsequent 
ASCT. 
 
Of the 110 patients who underwent PBSC harvesting in the MM X trial, after all 
attempts, 64% were able to mobilise and harvest an adequate dose to allow salvage 
ASCT.  Only 32 proceeded to a second attempt and of those only 4 to a third attempt.  
Interestingly the rate of successful harvesting remained high at these subsequent 
attempts suggesting more patients could have benefitted from repeated mobilisations, 
which is in keeping with the majority of previous data
24-26
 .  Nevertheless, only 30 
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patients left the trial due to inability to mobilise sufficient stem cells.  Thus, the majority 
of patients are able to harvest sufficient stem cells after bortezomib salvage therapy for 
a second high dose procedure. 
 
The mobilisation regimens used for PBSC harvesting within the trial were at the 
discretion of the treating physicians and accordingly a range of regimens was employed.  
The majority of patients received cyclophosphamide and G-CSF, and a smaller number 
G-CSF alone, in keeping with standard practice
18,27
.  A number of mobilisations also 
employed the CXCR4 antagonist, Plerixafor, particularly for second and third 
mobilisation attempts, either as a planned treatment or to salvage a failed mobilisation 
with other agents.  As suggested by previous retrospective studies
24,25,28,29
, the drug was 
effective in this context, and improved yields were seen compared to G-CSF alone, as in 
the setting of harvesting during first line treatment
30
.  There is ongoing debate about 
the relative costs and efficacies of Plerixafor vs. chemotherapy based regimens
31
.  Since 
mobilisation regimen was not a controlled randomisation within our trial a direct 
comparison is therefore not possible, although similar efficacies were seen (Figure 2 and 
Supplementary Table 1).  Since the inception of this study Plerixafor has gained a 
product license and is funded by the UK NHS for both mobilisation after a previous failed 
attempt and pre-emptive mobilisation in patients with inadequate CD34
+
 mobilisation 
on the planned day of harvesting, and it is therefore likely that its use for remobilisation 
at relapse will increase.  Given that the majority of patients who failed to harvest a 
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successful stem cell dose were not exposed to Plerixafor, it is likely that regular use of 
the drug may well further increase the proportion of successful harvests in the future. 
 
Stem cell remobilisation was well tolerated, with neutropenia, thrombocytopenia and 
infection being the main toxicities encountered, at frequencies similar to published 
reports of harvesting after first line therapy
30,32-34
.  Sensory neuropathy was frequently 
reported during mobilisation and harvesting, although this almost certainly relates to 
the preceding treatment with bortezomib.  Reassuringly, we did not see a marked 
increase in toxicity with repeated mobilisation attempts, in keeping with the published 
data on toxicity of remobilisation
35
.  Given the efficacy of salvage ASCT in this context 
and the high chance of success already discussed, further attempts after one failed 
mobilisation are therefore both rational and safe.   
 
Patients undergoing ASCT with cells previously stored (PBSC1), harvested after re-
induction within the trial (PBSC2) or a combination of the two (PBSCMix) had similar 
outcomes: there were no statistically significant differences in neutrophil engraftment 
or time to discharge between groups.  Platelet engraftment was slightly slower in the 
PBSC2 and PSBCMix groups, possibly reflecting the lower mean stem cell dose in those 
groups, although other authors have also reported delayed platelet engraftment in this 
setting in a small cohort
36
.  Responses by IMWG criteria were comparable.  In comparing 
the outcomes of the PBSC2/PBSCMix and PBSC1 groups, it is important to acknowledge 
that since re-mobilisation incurs a further period of time prior to ASCT, a selection bias 
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may be introduced whereby only those with better-performing disease (i.e. those 
remaining in remission) can undergo re-harvesting.  Since median time from PAD to 
remobilisation was 21 days, indicating the majority of patients were remobilised rapidly 
once recovered from induction, this is not expected to impact significantly upon results.  
Whilst it is tempting to speculate that bortezomib re-induction, or therapy preceding it, 
might alter the characteristics of the harvested stem cell product, no significant 
differences in outcome have thus far been seen between groups.  Nonetheless, there is 
potential for genetic or epigenetic damage to stem cells by preceding therapy, which 
might plausibly increase the risk of sequelae such as myelodysplasia.  Previous 
retrospective studies have suggested an increased risk of myelodysplasia in patients 
receiving stem cells harvested after prior therapy
24,37
, particularly in more heavily pre-
treated cohorts
24,37
; ongoing clinical follow-up of the groups and planned companion 
studies in this prospective study to evaluate key biological characteristics of stem cells 
stored previously and harvested after bortezomib-based re-induction will allow further 
characterisation of the stem cell products and differences in outcomes.  Importantly, the 
toxicities of ASCT were similar to published reports
3,7
, irrespective of stem cell source. 
 
In light of the findings of the MM X trial, mobilisation and harvesting of sufficient PBSC 
for at least two ASCT procedures is a rational strategy after 1
st
 induction treatment for 
all transplant eligible patients.  Recent data suggest that with modern harvesting 
regimens, for example incorporating Plerixafor
38
, the vast majority of patients can 
achieve this target.  It should be emphasised that despite the encouraging results 
Stem cell harvesting in relapsed myeloma  Parrish et al. 
Page 15 
presented here some patients were unable to proceed to ASCT2 due to inability to 
mobilise PBSC.  Other researchers have reported variables which may predict poor 
remobilisation at relapse, such as thrombocytopenia, anaemia, bone marrow cellularity, 
hypoalbuminaemia etc.
37
 and this is of interest, but such observations are unlikely to be 
helpful in clinical decision making since these variables can be assessed only once cells 
are needed and not available.  We therefore consider that the goal should always be to 
harvest enough PBSC at first line to allow a second ASCT at relapse.  Nevertheless, for 
many current and future patients, PBSC will not be stored for a second high dose 
procedure  ? there are many reasons for this including storage limitations, costs 
associated with long term stem cell storage and concerns about their viability, lack of 
evidence for second ASCT at the time of harvesting, inability to harvest sufficient cells 
with older, less effective regimens and the fact that in many healthcare economies a 
second HDT/ASCT may not be affordable or funded (for example Medicare in the United 
States will reimburse for only one ASCT in those patients achieving at least a PR in 
response to chemotherapy; tandem or multiple transplantation is not covered).  Indeed, 
in our trial, of the 276 patients who completed re-induction therapy, only 149 had an 
adequate stored PBSC dose from their previous transplant to allow a second ASCT.  For 
patients in this situation, mobilisation and harvesting after a bortezomib-doxorubicin-
dexamethasone re-induction regimen is feasible and safe, and importantly it facilitates a 
superior therapeutic option for patients with myeloma at first relapse. 
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Figures and Tables 
 
 
Figure 1: Trial CONSORT Diagram.  SD=stable disease, PD=progressive disease, 
PBSC=peripheral blood stem cell, ASCT= autologous stem cell transplant.  A full consort 
diagram for the trial is published (Cook et al.
17
). 
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Figure 2:  Mobilisation regimens employed and percentage of mobilisation attempts 
leading to successful PBSC harvest at first, second and third mobilisation attempts.  
Error bars show 95% confidence intervals. 
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Figure 3: Kaplan-Meier curves after ASCT for patients receiving PBSC harvested prior to 
trial entry (PBSC1), re-harvested in the trial (PBSC2) and a combination of both sources 
(PBSCMix).  
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 Registered 
patients 
(n=297) 
Remobilised 
patients 
(n=110) 
Patients undergoing ASCT 
PBSC1 
(n=42) 
PBSC2 
(n=29) 
PBSCMix 
(n=11) 
p-value
#
 
Gender   Male 208 (70.0%) 76 (69.1%) 31 (73.8%) 20 (69.0%) 10 (90.9%) 
0.413 
   Female 89 (30.0%) 34 (30.9%) 11 (26.2%) 9 (31.0%) 1 (9.1%) 
Age at randomisation (median) 61 62 61 63 59 0.370 
Myeloma isotype IgG 190 (64.0%) 69 (62.7%) 26 (61.9%) 19 (65.6%) 8 (72.7%) 
0.955 
   IgA 55 (18.5%) 22 (20%) 6 (14.3%) 5 (17.2%) 2 (18.2%) 
   IgM/IgD 3 (1.0%) 1 (0.9%) 1 (2.4%) 0 0 
   Light chain 26 (8.8%) 11 (10%) 5 (11.9%) 2 (6.9%) 0 
   Non-secretory 9 (3.0%) 4 (3.6%) 1 (2.4%) 2 (6.9%) 0 
   Missing 14 (4.7%) 3 (2.7%) 3 (7.1%) 1 (3.4%) 1 (9.1%) 
Light chain isotype Lambda 82 (27.6%) 30 (27.3%) 15 (35.7%) 4 (13.8%) 3 (27.3%) 
0.326    Kappa 185 (62.3% 68 (61.8%) 21 (50.0%) 20 (69.0%) 6 (54.5%) 
   Missing 30 (10.1% 3 (2.7%) 6 (14.3%) 5 (17.2% 2 (18.2%) 
ISS stage at diagnosis I 88 (29.6%) 34 (30.9%) 9 (21.4%) 12 (41.4%) 2 (18.2%) 
0.049 
   II 93 (31.3%) 28 (25.5%) 11 (26.2%) 8 (27.6%) 1 (9.1%) 
   III 38 (12.8%) 17 (15.5%) 10 (23.8%) 1 (3.4%) 5 (45.5%) 
   Missing 78 (26.3%) 31 (28.2%) 12 (28.6%) 8 (27.6%) 3 (27.3%) 
Previous therapies Vincristine 84 (28.8%) 33 (30%)* 14 (33.3%) 10 (35.7%) * 4 (36.4%) 0.821 
   Thalidomide 202 (68.9% 75 (68.2%) 28 (66.7%) 23 (79.3%) 8 (72.7%) 0.515 
   Bortezomib 13 (4.4%) 6 (5.5%)* 2 (4.8%) 0 * 0 0.554 
   Bisphosphonate 226 (77.1%) 85 (77.3%) 35 (83.3%) 21(72.4%) 7 (63.6%) 0.288 
Response to prior ASCT sCR/CR 157 (54.1%)* 61 (55.5%) 23 (54.8%) 17 (58.6%) 6 (54.5%) 
0.282    VGPR/PR 119 (41.0%)* 45 (40.9%) 17 (40.5%) 12 (41.4%) 3 (27.3%) 
   SD 14 (4.8%)* 4 (3.6%) 2 (4.8%) 0 2 (18.2%) 
PFS after 1
st
 ASCT /years (median, range)* 2.5 (0.4-12.4) 2.6 (1-12.4) 2.3 (1.1-6.6) 3.0 (1.3-12.2) 3.4 (1.6-12.4) 0.031 
Time from diagnosis to randomisation 
/years (median, range)* 
  3.6 (2.2-8.9) 4.8 (2.7-13.3) 4.8 (29-13.6) 0.019 
Time from registration to randomisation 
/months (median, range) 
  3.5 (1.6-4.9) 4.9 (3-9.7) 4.6 (3.2-5.5) <0.001 
Cytogenetics at trial entry*  
 Patients with available data 149 55 22 8 7  
 t(4;14)  14 (9.4%) 6 (10.9%) 3 (13.6%) 2 (25%) 0 0.079 
 t(11;14) 15 (10.1%) 5 (9.1%) 1 (4.5%) 0 1 (14.3%) 0.065 
 t(14;16) 3 (2.0%) 1 (1.8%) 0 0 0  
 17p del 11 (7.4%) 2 (3.6%) 2 (9.1%) 1 (12.5%) 0 0.102 
 13q del 58 (38.9%) 21 (38.2%) 15 (68.2%) 2 (25%) 3 (42.9%) 0.023 
 Hyperdiploidy 20 (13.4%) 11 (20%) 2 (9.1%) 1 (12.5%) 0 0.102 
 Adverse risk cytogenetics 24 (16.1%) 7 (12.7%) 4 (18.2%) 2 (25%) 0 0.085 
Table 1: Pre-ASCT characteristics by stem cell source subsequently used. 
* Data not available for all patients; figures and percentages given are for known 
patients.  Cytogenetics are by interphase fluorescence in-situ hybridisation 
#P-value compares distribution of characteristics by stem cell source (PBSC1 vs. PBSC2 
vs. PBSCMix).  Continuous variables are compared using the Kruskal-Wallis test and 
ĐĂƚĞŐŽƌŝĐĂůǀĂƌŝĂďůĞƐƵƐŝŶŐ&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ ? 
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 All grade toxicity, n (%) Grade 3-4 toxicity, n (%) p 
Total number of mobilisation 
attempts undertaken 
1 
(n=74) 
2 
(n=32) 
3 
(n=4) 
1 
(n=74) 
2 
(n=32) 
3 
(n=4) 
 
Neutropenia 23 (31.1) 13 (40.6) 2 (50) 15 (20.3) 8 (25) 1 (25) 0.588 
Thrombocytopenia 30 (40.5) 14 (43.8) 2 (50) 11 (14.9) 8 (25) 0 0.604 
Infection 8 (10.8) 6 (18.8) 1 (25) 4 (5.4) 4 (12.5) 1 (25) 0.471 
Nausea 11 (14.9) 7 (21.9) 0 1 (1.4) 1 (3.1) 0 0.508 
Vomiting 6 (8.1) 4 (12.5) 0 1 (1.4) 2 (6.3) 0 0.608 
Skin toxicity 3 (4.1) 2 (6.25) 0 0 1 (3.1) 0 0.475 
Pyrexia 1 (1.4) 4 (12.5) 0 0 1 (3.1) 0 0.127 
Neuropathy (motor) 1 (1.4) * 0 0 0 * 0 0 - 
Neuropathy (sensory) 21 (28.4) 10 (31.3) 1 (25) 4 (5.4) # 3 (9.4) 0 0.920 
Lethargy 12 (16.2) 8 (25) 0 0 0 0 0.729 
Anaemia 7 (9.5) 2 (6.3) 0 0 0 0 - 
Diarrhoea 3 (4.1) 3 (9.4) 0 0 0 0 - 
Thrombosis 1 (1.4) 1 (3.1) 0 1 (1.4) 1 (3.1) 0 - 
All other toxicities A? ? ?A? ? ? ? ? A? ? ?A? ? ? ? ? A   ?A? ? ? ? 0 0 0 - 
Safety data missing 1 (1.4) 0 0 1 (1.4) 0 0 - 
Table 2: Frequency of toxicities reported between end of induction and randomisation, 
in patients undergoing 1, 2 and 3 attempts at PBSC mobilisation.  * 1 patient 
experienced motor neuropathy of unknown grade.  # 2 further patients experienced 
sensory neuropathy of unknown grade.  P-ǀĂůƵĞƐĂƌĞĨŽƌ&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚĐŽŵƉĂƌŝŶŐ
all-grades of toxicity across groups defined by the number of attempts at PBSC 
mobilisation.  
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 PBSC1 
(n=42) 
PBSC2 
(n=29) 
PBSCMix 
(n=11) 
p-value
#
 
Stem cells infused /x10
6
 CD34
+
 /kg: 
median (range) 
3.2 
(1.6-13.6) 
2.9  
(1.4-7.0) 
2.6  
(2.1-6.6) 
NS 
Days to neutrophils >0.5x10
9
/L: 
median (range) 
12.0 
(3-25) 
12 .0 
(4-25) 
12 .0 
(11-33) 
NS 
Days to platelets >20x10
9
/L: 
median (range) 
12.5 
(7-105) 
12 
(6-82) 
16  
(9-33) 
NS 
Days to platelets >50x10
9
/L: 
median (range) 
18.0 
(10-179) 
21.0  
(6-124) 
24.0  
(16-146) 
0.033 
Days to discharge after ASCT: 
median (range) 
16.0 
(9-45) 
16.0  
(12-33) 
18.0  
(12-50) 
NS 
 
Table 3: ASCT procedure characteristics by stem cell source. 
#P-value compares distribution of characteristics by stem cell source.  Continuous 
variables are compared using the Kruskal-Wallis test and categorical variables using 
&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ ? 
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Supplementary Table Legends 
Supplementary Table 1: Mobilisation regimens and stem cell harvest outcomes.  
Abbreviations: G-CSF: granulocyte colony stimulating factor, ESHAP: etoposide, 
methylprednisolone, cytarabine and cisplatin.  * Percentage of collections where the 
yield is known and is >2x10
6
 CD34
+
 /kg. 
 
Supplementary Table 2: Sensory neuropathy (CTCAE grade) for patients at the end of 
PAD and then at the end of mobilisation. 
 
Supplementary Table 3: Frequency of toxicities reported during high dose melphalan 
ĂŶĚ^d ?WǀĂůƵĞƐĂƌĞĨŽƌ&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚĐŽŵƉĂƌŝŶŐĂůů-grades of toxicity across 
groups defined by the source of stem cells (PBSC1, PBSC2, PBSCMix).   
 
Supplementary Table 4: Maximal responses to stem cell transplant.  1 patient died 
within 100 days of ASCT  ? the stem cell source used for this patient is not known.  6 
patients who were randomised to ASCT did not undergo the procedure. 
 
Supplementary Table 5: Co-investigators contributing to this study. 
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